Journal
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
Volume 36, Issue -, Pages 37-50Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejpn.2021.11.009
Keywords
Diagnostic criteria; Epilepsy with myoclonic-atonic seizures; Myoclonic-atonic seizures; Genetic heterogeneity; Doose syndrome
Categories
Ask authors/readers for more resources
This review proposes updated diagnostic criteria for epilepsy with myoclonic-atonic seizures (EMAS). The criteria emphasize age of onset, seizure types, and specific electroclinical features. The article suggests redefining EMAS as genetic generalized epilepsy, based on recent genetic studies, and highlights the possibility of EMAS evolving into epileptic encephalopathy.
Purpose: The aim of this review is to propose the updated diagnostic criteria of epilepsy with myoclonic-atonic seizures (EMAS), which is a recent subject of genetic studies. Although EMAS has been well known as Doose syndrome, it is often difficult to diagnose due to a lack of consensus regarding some of the inclusion criteria. Along with progress in molecular genetic study on the syndrome, it becomes important to recruit electroclinical homogeneous EMAS patients, hence the validity of the clinical criteria should be verified based on recent clinical researches. At present, the most updated ILAE diagnostic manual of EMAS includes: (1) normal development and cognition before the onset of epilepsy; (2) onset of epilepsy between 6 months and 6 years of age (peak: 2-4 years); (3) myoclonic-atonic seizures (MAS) are mandatory (4) presence of generalized spike-wave discharges at 2-3 Hz without persistent focal spike discharges; and (5) exclusion of other myoclonic epilepsy syndromes. In the criteria, we should emphasize that the age at onset of MAS is between 2-5 years in (2), presence of myoclonic-atonic, atonic or myoclonic-flexor seizures (MASs) causing drop attacks associated with generalized spike-wave discharges is mandatory in (3), and epileptic spasms causing drop attacks must be excluded in (5). In the modified criteria, I propose that EMAS is redesignated as genetic generalized epilepsy with MASs, consistent with the familial genetic study conducted by Doose and the recent identification of candidate genes. It should also be noted that EMASs evolves to transient or long-lasting epileptic encephalopathy. (C) 2021 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available